Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New NGS Solutions Provide Powerful Tool for Myeloid Research with Highly Efficient Workflow

By LabMedica International staff writers
Posted on 06 Oct 2022

OGT (Oxford, UK), a Sysmex Group (Kobe, Japan) company, has launched several new solutions to support its growing next-generation sequencing (NGS) portfolio. More...

These include the SureSeq Myeloid Plus panel, which has been designed to detect aberrations in genes implicated in a variety of Myeloid disorders. Additionally, OGT has also launched a new improved library preparation workflow - the OGT Universal NGS Complete Workflow, compatible with its hematology, inherited and rare disease NGS panels - significantly reducing hands-on time and complemented by updated Interpret NGS Analysis software.

The SureSeq Myeloid Plus panel is the most recent addition to OGT’s hematology NGS portfolio. Having been meticulously designed along-side leading cancer experts, the new panel is able to detect a comprehensive range of aberrations including SNVs, indels, ITDs and PTDs within 49 genes. These genes cover those associated with myeloid disorders including acute myeloid leukemia, myeloproliferative neoplasms and myelodysplastic syndrome among others. Thanks to OGT’s vast expertise in bait design, the Myeloid Plus panel delivers unparalleled coverage uniformity for low frequency variants, even in difficult-to-sequence AT/GC rich regions and challenging regions covering ITDs and PTDs, which are common somatic variants in acute myeloid leukemia (AML) often associated with poor prognosis and an aggressive form of the disease. The power of the Myeloid Plus panel stands testament to the benefits of hybridization capture over PCR enrichment for unrivalled levels of sensitivity and uniformity of coverage.

To support researchers using the SureSeq Myeloid Plus panel, and all of OGT’s SureSeq hematology and CytoSure NGS panels, the new Universal NGS Complete Workflow has been developed. By reducing the number of clean-up steps and QC requirements, library preparation can be completed in just four and a half hours, with a 40% saving of hands-on time. By combining several steps, and introducing sample pooling, the reduced workflow complexity not only decreases the potential for error, but also saves on plastic waste and costs.

Compared to the previous SureSeq workflow, the updated version requires no additional expensive laboratory equipment, making the process much more amenable to automation, and therefore ready for the future. To supplement this new and improved workflow, OGT’s renowned Interpret NGS Analysis software (V3.5) has been upgraded with improvements in CNV interpretation, annotation, visualization and sample data import and display. Unlike many other NGS providers, OGT provides complimentary NGS software with its NGS panels, demonstrating the company’s commitment to sharing technology, and technical expertise to support NGS research around the globe.

“At OGT, we are experts in delivering high efficiency NGS workflows with best-in-class gene panels, software, and library preparation solutions,” said Adrian Smith, Chief Executive Officer of OGT. “Thanks to our unmatched expertise in bait design, and through partnering with leading cancer experts, we have developed a powerful tool for myeloid research with a highly efficient workflow. This enables clinical researchers to quickly and confidently detect all relevant variants in one simple assay. NGS is a key area of expertise for OGT, and we have exciting plans and possibilities for the future.”

Related Links:
OGT
Sysmex Group


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.